Photos by Mark Lee
CORDLIFE GROUP took its investment story right to the doorstep of of China's investment community when its CEO, Jeremy Yee, presented to 28 funds on Thursday (8 Jan) in Shenzhen.
The event: "Scaling New Heights-Asia Investment Forum 2015".
It was the 5th annual event organised by Financial PR and Asia Fund Space with support from the China Enterprise Reputation & Credibility Association (Overseas) and the Hong Kong Investor Relations Association.
Cordlife, a private cord blood bank operator listed on the Singapore Exchange, has a significant exposure to the cord-blood banking business in China through its 10% stake in China Cord Blood Corporation, which is listed on the New York Stock Exchange.
That stake is set to rise to 14.2% in 2017 when it converts its holding of the convertible bonds of China Cord Blood Corporation, China's leading cord blood bank operator.
An equity stake aside, Cordlife has a strategic business partnership with China Cord Blood Corporation.
The two companies jointly launched a cord-lining storage service in China in July 2014.
Apart from China, Cordlife has a presence in mature markets Singapore and Hong Kong and high growth markets like India, Indonesia and the Philippines.
Maybank Kim Eng has a 'buy' call and a target price of $1.30 for Cordlife's shares (which traded recently at 91 cents).
The research house cited catalysts such as possible maiden dividends from China Cord Blood Corporation and better sales traction in China.
Recent story: @ CORDLIFE's EGM: Questions On Loan Repayment, China Dream, Etc